市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
| 股票 | BioAge Labs, Inc. | - | - |
AIStockmoo 评分
1.5
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.50 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 内部持股比例 | 3.62% |
| 机构持股比例 | 70.68% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Sofinnova Investments, Inc. | 30 Sep 2024 | 2,304,901 |
| Redpoint Management, Llc | 30 Sep 2024 | 383,255 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (Morgan Stanley, 830.23%) | 购买 |
| 中 | 7.00 (62.79%) | |
| 低 | 7.00 (Citigroup, 62.79%) | 保留 |
| 7.00 (Jefferies, 62.79%) | 保留 | |
| 平均值 | 18.00 (318.61%) | |
| 总计 | 1 购买, 2 保留 | |
| 平均价格@调整类型 | 11.71 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 09 Dec 2024 | 7.00 (62.79%) | 保留 | 4.65 |
| 21 Oct 2024 | 45.00 (946.51%) | 购买 | 25.83 | |
| Jefferies | 09 Dec 2024 | 7.00 (62.79%) | 保留 | 4.65 |
| 21 Oct 2024 | 42.00 (876.74%) | 购买 | 25.83 | |
| Morgan Stanley | 21 Oct 2024 | 40.00 (830.23%) | 购买 | 25.83 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合